Scandion Oncology expands clinical development with internationalization of the CORIST-trial
The CORIST phase II-trial studying Scandion Oncology’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer is now approved to recruit patients in Germany and Spain in addition to Denmark.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, now further upscales its efforts in clinical development by expanding the ongoing CORIST phase II-trial with its lead compound SCO-101 to also include patients in Germany and Spain. The Federal Institute for